• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Obagi Medical Announces the Launch of ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate

    9/9/24 9:37:49 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $WALD alert in real time by email

    Obagi Medical_Elastiderm New Products

     Obagi Medical_Key Visual

    NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation and pioneer in medical-grade skincare and a subsidiary of Waldencast plc, (NASDAQ:WALD) ("Waldencast"), proudly announces the launch of two groundbreaking skincare products: ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate. Both products deliver transformative results, leveraging cutting-edge technology and advanced formulations to enhance skin appearance and texture.

    The ELASTIDERM® Lift Up & Sculpt Facial Moisturizer is clinically proven to visibly lift and sculpt facial contours. This advanced moisturizer actively supports skin's elasticity through Obagi's patented Bi-Mineral Contour Complex™, which combines Zinc, Copper, and Malonate to help support skin elasticity and target the signs of skin aging. It incorporates Polyglutamic Acid (PGA), a peptide known for its superior hydrating properties to provide intense hydration and help re-plump fine lines and wrinkles. The result is a visibly lifted, sculpted appearance with improved fullness, smoothness, and skin texture in just 6 weeks.*

    The ELASTIDERM® Advanced Filler Concentrate offers a targeted solution for fine lines and wrinkles formulated with Acetyl Hexapeptide-1, an ingredient renowned for its effective re-plumping and wrinkle-smoothing benefits. The concentrate, applied topically with a precision applicator, delivers immediate filling effects for existing fine lines, while helping diminish wrinkles over time. This non-injectable solution is designed to provide a visibly lifted and youthful appearance by targeting emerging fine lines and wrinkles.*

    Eman Kadhim, Head of Scientific Communications & Upstream Innovation at Waldencast, commented, "The release of the latest ELASTIDERM® products marks a notable advancement in dermatological research. These products incorporate our proprietary Bi-Mineral Contour Complex™ and Acetyl Hexapeptide-1, which were rigorously tested and proven effective in enhancing skin elasticity and hydration. These formulations enhance overall skin texture, underscoring our commitment to integrating cutting-edge scientific research and ingredients into practical, effective skincare solutions."

    Justin Giouzepis, Chief Marketing Officer of Obagi Cosmeceuticals, added, "At Obagi, we are dedicated to supporting our valued physician and professional partners by providing products that enhance their anti-aging treatments. Our formulations are designed to complement in-office procedures, ensuring a comprehensive approach to skincare. Additionally, for those who seek transformative solutions for fine lines, wrinkles, and aging skin outside of clinical settings, the ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate products offer effective, high-quality alternatives to help them achieve their skincare goals."

    ELASTIDERM® Lift Up & Sculpt Facial Moisturizer, priced at $135, and the ELASTIDERM® Advanced Filler Concentrate, priced at $115, are now available through partnering professional channels. They will be available for customers to purchase on Obagi.com on September 23rd.

    *Results based on 2024 clinical tests. Data on file at Obagi Cosmeceuticals LLC.

    About Obagi Medical

    Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, refined with a legacy of 35 years' experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. Backed by science and trusted by professionals, Obagi empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand's website, https://www.obagi.com.

    About Waldencast

    Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.

    Media Contact:

    [email protected]

    Photos accompanying this announcement are available at

    https://www.globenewswire.com/NewsRoom/AttachmentNg/798b5c0e-14fc-4953-a72e-1d23eb42fe26

    https://www.globenewswire.com/NewsRoom/AttachmentNg/6add0355-4134-42d8-a887-81280d66262d



    Primary Logo

    Get the next $WALD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WALD

    DatePrice TargetRatingAnalyst
    1/14/2026$2.00Buy
    Jefferies
    11/25/2025$3.00Outperform → Market Perform
    Telsey Advisory Group
    4/22/2025$5.00Buy
    Alliance Global Partners
    12/16/2024$4.30Hold
    TD Cowen
    10/25/2024$5.00Buy
    Canaccord Genuity
    5/1/2024$10.00 → $8.00Outperform
    Telsey Advisory Group
    7/24/2023Outperform → Mkt Perform
    Raymond James
    9/9/2022$12.00Buy
    DA Davidson
    More analyst ratings

    $WALD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Waldencast plc with a new price target

    Jefferies resumed coverage of Waldencast plc with a rating of Buy and set a new price target of $2.00

    1/14/26 8:45:39 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc downgraded by Telsey Advisory Group with a new price target

    Telsey Advisory Group downgraded Waldencast plc from Outperform to Market Perform and set a new price target of $3.00

    11/25/25 8:37:06 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Alliance Global Partners initiated coverage on Waldencast plc with a new price target

    Alliance Global Partners initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00

    4/22/25 9:24:54 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    SEC Filings

    View All

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    3/13/26 6:47:02 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 20-F filed by Waldencast plc

    20-F - Waldencast plc (0001840199) (Filer)

    3/13/26 6:46:32 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    3/11/26 4:16:12 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Brousset Michel

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 12:12:49 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Souza Cristiano

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 11:25:15 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Thompson Motta Roberto Moses

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 11:24:08 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible Youthfulness

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin's age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously. At the cor

    3/24/26 8:35:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

    NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

    3/19/26 8:29:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Financials

    Live finance-specific insights

    View All

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

    LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned

    3/11/26 4:05:00 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update

    Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel expansion and sell-out acceleration but softer performance in Q3 2025 in international markets Company advances key strategic initiatives, including expansion into medical aesthetics through the Novaestiq acquisition and strengthened balance sheet following the sale of the Obagi Japan trademark and credit facility refinancing Waldencast updates FY 2025 guidance to reflect current trends and purposeful investments to drive long-term growth LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NA

    11/24/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Leadership Updates

    Live Leadership Updates

    View All

    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

    NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

    3/19/26 8:29:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Shareholders Elect Four Independent Directors to the Six Flags Board

    Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

    6/25/25 5:00:00 PM ET
    $BUD
    $CBRL
    $DG
    Beverages (Production/Distribution)
    Consumer Staples
    Restaurants
    Consumer Discretionary

    Milk Makeup to Launch at Ulta Beauty This Spring

    The New York City based award-winning clean color cosmetics brand will expand to select Ulta Beauty stores nationwide and online, marking a significant milestone since its debut in 2016 NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Milk Makeup, the trailblazing clean beauty brand celebrated for its iconic, high-performance formulas, inclusive ethos and part of the Waldencast plc (NASDAQ:WALD) platform, is thrilled to announce an expansion into the nation's largest beauty retailer, Ulta Beauty. Beginning this spring, Milk Makeup's cult-favorite products, including the 13x award-winning Hydro Grip Primer and internet-breaking Cooling Water Jelly Tints will be available in 600+ Ulta Beauty stores nat

    1/28/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Waldencast plc (Amendment)

    SC 13D/A - Waldencast plc (0001840199) (Subject)

    2/9/24 6:25:08 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G filed by Waldencast plc

    SC 13G - Waldencast plc (0001840199) (Subject)

    2/1/24 5:17:40 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G/A filed by Waldencast plc (Amendment)

    SC 13G/A - Waldencast plc (0001840199) (Subject)

    1/31/24 10:23:25 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary